Could a gut microbiome transplant ease axial spondyloarthritis?

NCT ID NCT06451588

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This trial tests whether transferring gut bacteria from a healthy donor (fecal microbiota transplantation, or FMT) can reduce disease activity in people with axial spondyloarthritis (axSpA) who haven't fully responded to biologic therapy. Participants receive a single enema with either donor FMT or their own stool (placebo) and are followed for a year. The study aims to see if FMT can improve symptoms like pain and fatigue and restore a healthier gut microbiome.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Fecal microbiota transplantation (FMT) via enema
What this could lead to
If effective, FMT could offer a new way to ease symptoms and reduce disease activity in people with axial spondyloarthritis who don't fully respond to biologics.
What could go wrong
This is a phase 2 trial, so results are uncertain. The effect may be modest or not lasting, and there are risks of adverse events from the procedure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANKYLOSING SPONDYLITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University Hospital North Norway

    RECRUITING

    Tromsø, 9038, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.